Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442812 | 0.73 | — | — | |
| SCHEMBL1038844 | 0.73 | — | — | |
| SCHEMBL5010227 | 0.73 | — | — | |
| SCHEMBL1898922 | 0.71 | — | — | |
| SCHEMBL8525523 | 0.69 | POLB (0.43) | POLBPARP1BRD4CREBBPMAOA | |
| SCHEMBL353825 | 0.69 | PARP1 (0.40) | POLBPARP1BRD4CREBBPMAOA | |
| SCHEMBL1107770 | 0.69 | POLB (0.43) | POLBPARP1BRD4CREBBPMAOA | |
| SCHEMBL4413227 | 0.68 | POLB (0.31) | POLB | |
| SCHEMBL3373132 | 0.68 | MAOA (0.37) | MAOAMAOB | |
| SCHEMBL11111141 | 0.68 | PARP1 (0.33) | PARP1BRD4CREBBPMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716231-B2 | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-06 | — | — | US | claimed |
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SMITH-SWINTOSKY VIRGINIA L (US) | 2012-03-15 | — | — | US | claimed |
| EP-1968574-A2 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | Janssen Pharmaceutica, N.V. (BE) | 2008-09-17 | — | — | EP | claimed |
| WO-2007075833-A2 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-05 | — | — | WO | claimed |
| EP-2760852-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013045681-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-04 | — | — | WO | disclosed |
| EP-2276481-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | Janssen Pharmaceutica, N.V. (BE) | 2011-01-26 | — | — | EP | disclosed |
| EP-2238122-A1 | PREPARATION OF SULFAMIDE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009120189-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009089210-A1 | PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N. V. (BE) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | CNR2, FAAH2, CCKBR | POLB 4390/4885PARP1 3849/4885BRD4 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.